ESC 365 - Patient views on lipoprotein (a) testing and treatment for secondary prevention of cardiovascular disease - results from 7 countries across 6 WHO regions from the INTERASPIRE study

Back

ESC2025 Premium Access

Patient views on lipoprotein (a) testing and treatment for secondary prevention of cardiovascular disease - results from 7 countries across 6 WHO regions from the INTERASPIRE study

Session: Lipoprotein(a) (1)

Topic: Secondary Prevention

Speaker: Doctor C. Jennings (Galway, IE)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Catriona Sian Jennings

University of Galway, Galway (Ireland)

20 presentations

0 follower

5 more presentations in this session

Combined effects of lipoprotein(a) and HDL cholesterol on cardiovascular mortality: a longitudinal study

Speaker: Professor B. Kim (Seoul, KR)

High lipoprotein(a) and high BMI jointly confer the highest risk of ASCVD in both primary and secondary prevention

Speaker: Mr P. Thomas (Copenhagen, DK)

Extra-virgin olive oil intake and lipoprotein A levels in the PREDIMED-Plus study

Speaker: Doctor J. Diaz-Gutierrez (Huelva, ES)

Lipoprotein(a), high-sensitive c reactive protein, and long-term survival after coronary artery bypass grafting

Speaker: Doctor S. Yuan (Beijing, CN)

Impact of lipoprotein(a) concentrations on atherosclerotic cardiovascular disease onset: a survival analysis

Speaker: Doctor V. Zorzanelli Rocha (Sao Paulo, BR)

Access the full session

Lipoprotein(a) (1)

Speakers: Doctor C. Jennings, Professor B. Kim, Mr P. Thomas, Doctor J. Diaz-Gutierrez, Doctor S. Yuan...

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources